CN1659156A - 新的胍基苯甲酰胺 - Google Patents

新的胍基苯甲酰胺 Download PDF

Info

Publication number
CN1659156A
CN1659156A CN018177182A CN01817718A CN1659156A CN 1659156 A CN1659156 A CN 1659156A CN 018177182 A CN018177182 A CN 018177182A CN 01817718 A CN01817718 A CN 01817718A CN 1659156 A CN1659156 A CN 1659156A
Authority
CN
China
Prior art keywords
substituted
unsubstituted
ethyl
amino
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN018177182A
Other languages
English (en)
Chinese (zh)
Inventor
P·A·伦霍维
D·楚
R·博伊斯
倪志杰
D·杜尔
E·托佐
K·约翰逊
D·麦莱斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of CN1659156A publication Critical patent/CN1659156A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/18—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN018177182A 2000-08-31 2001-08-31 新的胍基苯甲酰胺 Pending CN1659156A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23056500P 2000-08-31 2000-08-31
US60/230,565 2000-08-31
US24557900P 2000-11-06 2000-11-06
US60/245,579 2000-11-06

Publications (1)

Publication Number Publication Date
CN1659156A true CN1659156A (zh) 2005-08-24

Family

ID=26924350

Family Applications (1)

Application Number Title Priority Date Filing Date
CN018177182A Pending CN1659156A (zh) 2000-08-31 2001-08-31 新的胍基苯甲酰胺

Country Status (27)

Country Link
US (2) US6638927B2 (cg-RX-API-DMAC10.html)
EP (1) EP1409468B9 (cg-RX-API-DMAC10.html)
JP (1) JP4166567B2 (cg-RX-API-DMAC10.html)
KR (1) KR20030034163A (cg-RX-API-DMAC10.html)
CN (1) CN1659156A (cg-RX-API-DMAC10.html)
AP (1) AP2003002755A0 (cg-RX-API-DMAC10.html)
AT (1) ATE414067T1 (cg-RX-API-DMAC10.html)
AU (2) AU2001288604B2 (cg-RX-API-DMAC10.html)
BG (1) BG107639A (cg-RX-API-DMAC10.html)
BR (1) BR0113643A (cg-RX-API-DMAC10.html)
CA (1) CA2420694C (cg-RX-API-DMAC10.html)
CZ (1) CZ2003882A3 (cg-RX-API-DMAC10.html)
DE (1) DE60136571D1 (cg-RX-API-DMAC10.html)
DZ (1) DZ3415A1 (cg-RX-API-DMAC10.html)
EA (1) EA200300323A1 (cg-RX-API-DMAC10.html)
ES (1) ES2316467T3 (cg-RX-API-DMAC10.html)
HU (1) HUP0302067A2 (cg-RX-API-DMAC10.html)
IL (1) IL154604A0 (cg-RX-API-DMAC10.html)
MA (1) MA26948A1 (cg-RX-API-DMAC10.html)
MX (1) MXPA03001813A (cg-RX-API-DMAC10.html)
NO (1) NO20030929L (cg-RX-API-DMAC10.html)
NZ (1) NZ524897A (cg-RX-API-DMAC10.html)
PL (1) PL360698A1 (cg-RX-API-DMAC10.html)
PT (1) PT1409468E (cg-RX-API-DMAC10.html)
SI (1) SI21267A (cg-RX-API-DMAC10.html)
SK (1) SK3832003A3 (cg-RX-API-DMAC10.html)
WO (1) WO2002018327A2 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115850117A (zh) * 2022-11-15 2023-03-28 黎明化工研究设计院有限责任公司 一种制备1,4-环己烷二异氰酸酯的方法

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002081443A1 (en) * 2001-04-09 2002-10-17 Chiron Corporation Novel guanidino compounds
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
AU2002310409C1 (en) 2001-06-11 2008-04-17 Xenoport, Inc. Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
US20050124652A1 (en) * 2002-02-04 2005-06-09 Rustum Boyce Guanidino compounds
US20030195187A1 (en) * 2002-02-04 2003-10-16 Chiron Corporation Guanidino compounds
US20030207814A1 (en) * 2002-02-04 2003-11-06 Chiron Corporation Novel guanidinyl derivatives
US20070004743A1 (en) * 2002-02-25 2007-01-04 Xiao Linda L Intranasal administration of mc4-r agonists
PT1551834E (pt) * 2002-05-23 2010-09-30 Novartis Vaccines & Diagnostic Compostos de quinazolinona substituídos
US7125904B2 (en) * 2002-10-11 2006-10-24 Portela & C.A., S.A. Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation
ATE440827T1 (de) * 2002-12-04 2009-09-15 Ore Pharmaceuticals Inc Melanocortin-rezeptormodulatoren
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
EP1651229A1 (en) * 2003-05-23 2006-05-03 Chiron Corporation Guanidino-substituted quinazolinone compounds as mc4-r agonists
JP2005306839A (ja) * 2003-08-29 2005-11-04 Takeda Chem Ind Ltd 二環性ピペラジン化合物およびその用途
WO2005021555A1 (ja) * 2003-08-29 2005-03-10 Takeda Pharmaceutical Company Limited 二環性ピペラジン化合物およびその用途
US7368453B2 (en) * 2003-11-19 2008-05-06 Chiron Corporation Quinazolinone compounds with reduced bioaccumulation
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US7795448B2 (en) 2004-05-06 2010-09-14 Cytokinetics, Incorporated Imidazoyl-benzamide anti-cancer agents
US7504413B2 (en) 2004-05-06 2009-03-17 Cytokinetics, Inc. N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
EP1811986B1 (en) 2004-11-04 2014-03-26 XenoPort, Inc. Gabapentin prodrug sustained release oral dosage forms
US20070021433A1 (en) 2005-06-03 2007-01-25 Jian-Qiang Fan Pharmacological chaperones for treating obesity
WO2007022964A2 (de) 2005-08-24 2007-03-01 Abbott Gmbh & Co. Kg Hetaryl substituierte guanidinverbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
SI2348016T1 (sl) 2006-06-09 2016-10-28 Synact Pharma Aps Derivati fenil pirol aminogvanidina
GB0624987D0 (en) 2006-12-14 2007-01-24 Acure Pharma Ab Novel aminoguanidines as melanocortin receptor ligands
UA99555C2 (en) 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists
JP5514831B2 (ja) 2008-11-17 2014-06-04 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病の治療のための置換二環式アミン
CA2768577A1 (en) 2009-07-23 2011-01-27 Schering Corporation Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
US9044606B2 (en) 2010-01-22 2015-06-02 Ethicon Endo-Surgery, Inc. Methods and devices for activating brown adipose tissue using electrical energy
US8476227B2 (en) 2010-01-22 2013-07-02 Ethicon Endo-Surgery, Inc. Methods of activating a melanocortin-4 receptor pathway in obese subjects
US8785634B2 (en) 2010-04-26 2014-07-22 Merck Sharp & Dohme Corp Spiropiperidine prolylcarboxypeptidase inhibitors
WO2011143057A1 (en) 2010-05-11 2011-11-17 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
EP2579873A4 (en) 2010-06-11 2013-11-27 Merck Sharp & Dohme NOVEL PROLYLCARBOXYPEPTIDASE HEMMER
WO2012100342A1 (en) 2011-01-27 2012-08-02 Université de Montréal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
US10080884B2 (en) 2014-12-29 2018-09-25 Ethicon Llc Methods and devices for activating brown adipose tissue using electrical energy
US10092738B2 (en) 2014-12-29 2018-10-09 Ethicon Llc Methods and devices for inhibiting nerves when activating brown adipose tissue
HUE059638T2 (hu) 2019-05-10 2022-12-28 Synact Pharma Aps Ízületi gyulladásos betegségek kombinált kezelése
IL309102A (en) 2021-06-21 2024-02-01 Synact Pharma Aps Salts and formulations of phenyl pyrrole aminoguanidine

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3177218A (en) 1962-01-17 1965-04-06 Monsanto Chemicals Methylene-bis(2-guanidino-4-methylquinazoline)
DE2623846A1 (de) 1976-05-28 1977-12-15 Hoechst Ag 4-chinazolinyl-guanidine und verfahren zu ihrer herstellung
US4287341A (en) 1979-11-01 1981-09-01 Pfizer Inc. Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
EP0059597B1 (en) 1981-02-27 1986-04-23 Imperial Chemical Industries Plc Guanidino-substituted heterocyclic derivatives having histamine h-2 antagonist activity
EP0067508B1 (en) 1981-05-18 1985-10-30 Imperial Chemical Industries Plc Amidine derivatives
US4921939A (en) * 1985-03-19 1990-05-01 Universite Claude Bernard -Lyon 1 Sweetening agents
JPS6229566A (ja) 1985-07-30 1987-02-07 Taiyo Yakuhin Kogyo Kk 新規グアニジノメチル安息香酸誘導体
US4948891A (en) 1988-05-24 1990-08-14 Pfizer Inc. Benzamide protease inhibitors
US4874864A (en) 1988-05-24 1989-10-17 Pfizer Inc. Benzamide protease inhibitors
US4948901A (en) 1988-05-24 1990-08-14 Pfizer Inc. Benzamide protease inhibitors
JPH0276880A (ja) 1988-06-16 1990-03-16 Sankyo Co Ltd 悪液質改善治療剤
GB8926512D0 (en) 1989-11-23 1990-01-10 Pfizer Ltd Therapeutic agents
CA2032420A1 (en) 1989-12-22 1991-06-23 Akira Okuyama Guanidinobenzene derivatives
US5124328A (en) 1990-10-11 1992-06-23 Merck & Co., Inc. Morpholine derivatives compositions and use
EP0690851B1 (en) 1993-03-23 1999-05-19 Astra Aktiebolag Guanidine derivatives useful in therapy
SK16396A3 (en) 1993-08-12 1996-09-04 Astra Ab Amidine derivatives with nitric oxide synthetase activities
US5547966A (en) 1993-10-07 1996-08-20 Bristol-Myers Squibb Company Aryl urea and related compounds
US5599984A (en) 1994-01-21 1997-02-04 The Picower Institute For Medical Research Guanylhydrazones and their use to treat inflammatory conditions
US5637439A (en) 1994-11-07 1997-06-10 Mitsubishi Paper Mills Ltd. Photographic silver halide photosensitive material and method for developing the same
AU4534596A (en) 1995-02-09 1996-08-27 Novo Nordisk A/S Compounds with growth hormone releasing properties
DE19544685A1 (de) 1995-11-30 1997-06-05 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE19544687A1 (de) 1995-11-30 1997-06-05 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DK0891325T3 (da) 1996-03-29 2002-05-21 Searle & Co Para-substituerede phenylpropansyrederivater som integrinantagonister
ZA973850B (en) 1996-05-06 1997-12-02 Reddy Research Foundation Novel antidiabetic compounds having hypolipidaemic, anti-hypertensive properties, process for their preparation and pharmaceutical compositions containing them.
US6127343A (en) 1996-05-14 2000-10-03 Novo Nordisk A/S Somatostatin agonists and antagonists
WO1998007420A1 (en) 1996-08-23 1998-02-26 Agouron Acquisition Corp. Neuropeptide-y ligands
JP2001502712A (ja) 1996-10-31 2001-02-27 ノボ ノルディスク アクティーゼルスカブ 束縛されたソマトスタチン・アゴニスト及びアンタゴニスト
BR9713536A (pt) 1996-11-25 2000-11-07 Procter & Gamble Compostos heterocìclicos de guanidinila úteis como agonistas de adrenoceptores alfa-2
EP0981526B1 (en) 1997-05-02 2004-02-25 Dr. Reddy's Laboratories Ltd. Novel antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
AU742425B2 (en) * 1998-06-11 2002-01-03 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
DE19831710A1 (de) * 1998-07-15 2000-01-20 Merck Patent Gmbh Diacylhydrazinderivate
FR2784678B1 (fr) 1998-09-23 2002-11-29 Sod Conseils Rech Applic Nouveaux derives de n-(iminomethyl)amines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
WO2000047207A1 (en) 1999-02-09 2000-08-17 Bristol-Myers Squibb Company LACTAM INHIBITORS OF FXa AND METHOD
WO2000074679A1 (en) 1999-06-04 2000-12-14 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
WO2001010842A2 (en) 1999-08-04 2001-02-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
AU2001228681A1 (en) 2000-01-28 2001-08-07 Melacure Therapeutics Ab Novel aromatic amines and amides acting on the melanocortin receptors
WO2001055106A2 (en) 2000-01-28 2001-08-02 Melacure Therapeutics Ab Novel melanocortin receptor agonists and antagonists
GB0002059D0 (en) 2000-01-28 2000-03-22 Melacure Therapeutics Ab Novel aromatic amines
CA2403686C (en) 2000-03-23 2010-01-26 Merck & Co., Inc. Substituted piperidines as melanocortin receptor agonists
JP2003527444A (ja) 2000-03-23 2003-09-16 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体アゴニストとして作用するスピロピペリジン誘導体
GB0102668D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
WO2002081443A1 (en) 2001-04-09 2002-10-17 Chiron Corporation Novel guanidino compounds
PT1551834E (pt) 2002-05-23 2010-09-30 Novartis Vaccines & Diagnostic Compostos de quinazolinona substituídos

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115850117A (zh) * 2022-11-15 2023-03-28 黎明化工研究设计院有限责任公司 一种制备1,4-环己烷二异氰酸酯的方法
CN115850117B (zh) * 2022-11-15 2024-06-04 黎明化工研究设计院有限责任公司 一种制备1,4-环己烷二异氰酸酯的方法

Also Published As

Publication number Publication date
JP2004508304A (ja) 2004-03-18
CA2420694C (en) 2009-06-23
NO20030929D0 (no) 2003-02-27
PL360698A1 (en) 2004-09-20
AU8860401A (en) 2002-03-13
JP4166567B2 (ja) 2008-10-15
EA200300323A1 (ru) 2003-08-28
EP1409468B9 (en) 2009-07-29
NO20030929L (no) 2003-04-30
SI21267A (sl) 2004-02-29
MA26948A1 (fr) 2004-12-20
EP1409468A2 (en) 2004-04-21
DE60136571D1 (de) 2008-12-24
MXPA03001813A (es) 2004-11-01
US20030199499A1 (en) 2003-10-23
ATE414067T1 (de) 2008-11-15
BG107639A (bg) 2003-11-28
SK3832003A3 (en) 2003-11-04
WO2002018327A3 (en) 2002-08-08
AU2001288604B2 (en) 2005-02-24
IL154604A0 (en) 2003-09-17
US6638927B2 (en) 2003-10-28
AP2003002755A0 (en) 2003-06-30
BR0113643A (pt) 2004-03-02
KR20030034163A (ko) 2003-05-01
ES2316467T3 (es) 2009-04-16
US20020137939A1 (en) 2002-09-26
DZ3415A1 (fr) 2002-03-07
HUP0302067A2 (hu) 2003-09-29
US6995269B2 (en) 2006-02-07
EP1409468B1 (en) 2008-11-12
NZ524897A (en) 2004-08-27
PT1409468E (pt) 2009-01-28
CA2420694A1 (en) 2002-03-07
CZ2003882A3 (cs) 2003-09-17
WO2002018327A2 (en) 2002-03-07

Similar Documents

Publication Publication Date Title
CN1168727C (zh) 取代的苯并咪唑
CN1146540C (zh) 具有镇痛作用的新化合物及其用途
CN1247544C (zh) 带有杂芳基磺酰基侧链的邻氨基苯甲酰胺及其作为抗心律失常活性物质的用途
CN1296346C (zh) 酰化的6,7,8,9－四氢－5h－苯并环庚烯基胺和它们作为药物的用途
CN1241916C (zh) 新的二苯脲化合物、其制备方法和含有该化合物的药物组合物
CN1500081A (zh) 乙内酰硫脲及其在治疗糖尿病方面的用途
CN1143854C (zh) 新的2-(亚氨基甲基)氨基-苯基衍生物,其制备方法、作为药物的应用及其药物组合物
CN1214026C (zh) 吲哚－3－基衍生物
CN1555260A (zh) 氨基烷基取代的芳族二环化合物、它们的制备方法和它们作为药物的用途
CN1543461A (zh) 黑皮素受体配体
CN1753670A (zh) 新苯并咪唑和咪唑并吡啶衍生物及其作为药物的用途
CN1353695A (zh) 杂环取代的苯并咪唑、它们的制备及其用途
CN1306509A (zh) 取代苯甲酰胺类、其制备以及作为半胱氨酸蛋白酶抑制剂的应用
JP2004508304A (ja) 新規グアニジノベンズアミド
CN101039941A (zh) 氨基哌啶衍生物及其制备方法和作为黑皮质素受体激动剂的用途
CN1921848A (zh) 新型氮杂双环衍生物、其制备方法及包含其的药物组合物
CN1610664A (zh) 3－氮杂二环[3.1.0]己烷衍生物作为类阿片受体拮抗剂
CN1155562C (zh) 新的萘化合物、其制备方法及其药物组合物
CN1993321A (zh) 作为单胺再摄取抑制剂的3－氨基－1－芳基丙基吲哚类化合物
CN1795179A (zh) 新的咪唑衍生物、其制备方法和其作为药物的用途
CN1197863C (zh) 新的八氢－2H－吡啶并[1,2－a]吡嗪化合物、它们的制备方法和含有它们的药物组合物
CN1027536C (zh) 4，5，6，7-四氢化苯并咪唑衍生物制备方法
CN1906174A (zh) 新型苯并咪唑和咪唑并吡啶衍生物及其作为药物的应用
CN1062266C (zh) 脒衍生物以及含有该衍生物的血小板聚集抑制剂
CN1231465C (zh) 联苯磺酰氨腈、其制备方法和作为药物的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication